Sodium–glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real‐world, cohort data

Documenti analoghi

• Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all‐cause mortality in adults, compared with bisphosphonates: An analysis of real‐world, cohort data, with a systematic review and meta‐analysis
  di: Alex E. Henney, et al.
  Pubblicazione: (2024)
• Real‐world evaluation of teplizumab in type 1 diabetes: Progression to insulin requirement
  di: Sahana Mahesh, et al.
  Pubblicazione: (2025)
• Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes
  di: Jingchuan Guo, et al.
  Pubblicazione: (2024)
• Metabolic bariatric surgery is associated with reduced adverse hepatic and extrahepatic outcomes, and lower all‐cause mortality, in patients with steatotic liver disease
  di: Weronika Stupalkowska, et al.
  Pubblicazione: (2025)
• Cost‐effectiveness of sodium‐glucose cotransporter‐2 inhibitors in the treatment of diabetic nephropathy in Japan
  di: Keiko Maruyama‐Sakurai, et al.
  Pubblicazione: (2024)